Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12)

By sjmartinez • February 13, 2025

Chavez JC, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani C, Lin Y, Riedell PA, Kekre N, de Vos S, Wullf J, Williams CM, Winters J, Kloos IM Dr, Xu H, Neelapu SS. Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12). Blood. 2025 Feb 12:blood.2024027347. doi: 10.1182/blood.2024027347. Epub ahead of print. PMID: 39938019.

Tags: Hematology/Oncology, Publications

Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study

Duivon M, Christy F, Thomas E, Lequesne J, Castel H, Gaudin C, Delmas D, Boyault S, Rigal O, Bousrih C, Lévy C, Lerebours F, Di[...]

Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply

Bardia A, Schwaederle M, Curigliano G. Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply. N Engl J Med. 2025 Feb 20;392(8):830-831. doi:[...]

Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity?

Sedrak MS, Asnani A. Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity? JACC CardioOncol. 2025 Feb;7(2):122-124. doi: 10.1016/j.jaccao.2025.01.004. PMID:[...]